Plasma ATN biomarkers across AD continuum in Chilean cohort

This clinical biomarker study evaluated plasma amyloid, tau, and neurodegeneration (ATN) biomarkers in 318 older adults from a Chilean community- and clinic-based cohort to assess their ability to distinguish different stages along the Alzheimer's disease continuum. Participants included cognitively unimpaired (CU) individuals, those with subjective cognitive complaints (SCC), mild cognitive impairment (MCI), and Alzheimer's disease dementia (ADD). The study quantified plasma ATN biomarkers (Aβ42/Aβ40, p-tau217, NfL, and GFAP) using Simoa technology and assessed cognitive performance using standardized neuropsychological tests including the Addenbrooke's Cognitive Examination (ACE), Free and Cued Selective Reminding Test (FCSRT), and Technology–Activities of Daily Living Questionnaire (T-ADLQ). The research aimed to determine whether plasma biomarker combinations could effectively stage AD pathology and examine their clinical associations in an underrepresented Latin American population. Statistical analyses included ANCOVA models to examine group differences and linear regression to evaluate associations with cognitive performance.

This clinical biomarker study evaluated plasma amyloid, tau, and neurodegeneration (ATN) biomarkers in 318 older adults from a Chilean community- and clinic-based cohort to assess their ability to distinguish different stages along the Alzheimer's disease continuum. Participants included cognitively unimpaired (CU) individuals, those with subjective cognitive complaints (SCC), mild cognitive impairment (MCI), and Alzheimer's disease dementia (ADD). The study quantified plasma ATN biomarkers (Aβ42/Aβ40, p-tau217, NfL, and GFAP) using Simoa technology and assessed cognitive performance using standardized neuropsychological tests including the Addenbrooke's Cognitive Examination (ACE), Free and Cued Selective Reminding Test (FCSRT), and Technology–Activities of Daily Living Questionnaire (T-ADLQ). The research aimed to determine whether plasma biomarker combinations could effectively stage AD pathology and examine their clinical associations in an underrepresented Latin American population. Statistical analyses included ANCOVA models to examine group differences and linear regression to evaluate associations with cognitive performance. Additionally, supervised machine-learning models were implemented to classify participants across diagnostic categories based on plasma biomarker profiles.